NCT07461259 is a NA clinical trial of TWIICE Rise in Spinal Cord Injuries, sponsored by TWIICE.

Who is sponsoring NCT07461259?

NCT07461259 is sponsored by TWIICE.

What drugs are being tested in NCT07461259?

Interventions in NCT07461259: TWIICE Rise.

What condition does NCT07461259 study?

NCT07461259 studies Spinal Cord Injuries, Gait Disorders, Neurologic.

Is NCT07461259 still recruiting?

NCT07461259 is currently recruiting now. Last updated 10 March 2026.

Last reviewed 2026-03-10 · How we verify

NCT07461259

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Feasibility of TWIICE Rise - Phase 2

Recruiting now NA Last updated 10 March 2026

What this trial tests

NA trial testing TWIICE Rise in Spinal Cord Injuries in 15 participants. Currently enrolling.

Timeline

25 July 2023

Primary endpoint
31 July 2027

31 July 2027

Quick facts

Lead sponsor	TWIICE
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	15
Start date	25 July 2023
Primary completion	31 July 2027
Estimated completion	31 July 2027
Sites	1 location across Switzerland

Drugs / interventions tested

TWIICE Rise

Conditions studied

Spinal Cord Injuries — all drugs for Spinal Cord Injuries →
Gait Disorders, Neurologic — all drugs for Gait Disorders, Neurologic →

Sponsor

TWIICE — full company profile →

Who can join

Adults 18 to 70, any sex, with Spinal Cord Injuries or Gait Disorders, Neurologic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to assess the safety and the feasibility of two versions of TWIICE Rise for exoskeleton-assisted ambulation in patients with a spinal cord injury. This study is done in two phases: The first phase evaluates the safety and feasibility of TWIICE Rise 0.0 with 5 patients over 6 sessions in clinic. The second phase is being conducted with TWIICE Rise 1.0. This version has potentially improved functionalities based on feedback from Phase 1. Safety and feasibility will be assessed with 10 patients over 10 sessions in different settings (clinic, home, and community environment).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

NCT07109804 — Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury · NA · recruiting
NCT07472985 — Protocol for Rapid Onset of Mobilization in Patients With Traumatic Spinal Cord Injury II (PROMPT-SCI II) Trial · NA · recruiting
NCT07210411 — Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury · NA · recruiting
NCT07488793 — Remote Ischemic Conditioning for PwSCI · NA · recruiting
NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07461259 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by TWIICE
Last refreshed: 10 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07461259.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing